<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972840</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-308</org_study_id>
    <nct_id>NCT02972840</nct_id>
  </id_info>
  <brief_title>A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and
      rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle
      cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRC-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRC-assessed duration of response per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRC assessed time to response per the Lugano Classification for NHL in Arm 1 compared to Arm 2</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Lymphoma, Mantle Cell</condition>
  <arm_group>
    <arm_group_label>Acalabrutinib in combination with bendamustine and rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in combination with bendamustine and rituximab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib in combination with bendamustine and rituximab</intervention_name>
    <arm_group_label>Acalabrutinib in combination with bendamustine and rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo in combination with bendamustine and rituximab</intervention_name>
    <arm_group_label>Placebo in combination with bendamustine and rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ≥ 65 years of age.

          -  Pathologically confirmed MCL.

          -  MCL requiring treatment and for which no prior systemic anticancer therapies have
             been received.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

          -  Agreement to use highly effective forms of contraception during the study and 90 days
             after the last dose of acalabrutinib, 6 months after the last dose of bendamustine,
             or 12 months after the last dose of rituximab, whichever is longest .

        Exclusion Criteria:

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of first dose of
             study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart
             Association Functional Classification, or corrected QT interval (QTc) &gt; 480 msec
             (calculated using Friderica's formula: QT/RR0.33) at screening. Exception: Subjects
             with controlled, asymptomatic atrial fibrillation during screening are allowed to
             enroll on study.

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function,
             resection of the stomach, extensive small bowel resection that is likely to affect
             absorption, symptomatic inflammatory bowel disease, partial or complete bowel
             obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

          -  Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment), or intravenous anti infective
             treatment within 2 weeks before first dose of study drug.

          -  Concurrent participation in another therapeutic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shweta Gupta, BAMS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rudy Narace</last_name>
    <phone>1650-591-2800</phone>
    <phone_ext>176</phone_ext>
    <email>ace-ly-308@acerta-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>562-693-4477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-784-0038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060-1173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>770-333-2161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>516-488-2918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manhattan Hematology Oncology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-689-6791</phone>
      <phone_ext>228</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>330-492-3345</phone>
      <phone_ext>209</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-9324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>304-293-1683</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>November 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>ACP-196</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>acalabrutinib</keyword>
  <keyword>ACE-LY-308</keyword>
  <keyword>Treatment naive</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>non-Hodgkins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
